Sintilimab in combination with chemotherapy meets primary endpoint in the global Phase 3 ORIENT-15 study for the first-line treatment of oesophageal squamous cell carcinoma

This immunoglobulin G4 monoclonal antibody PD-1 inhibitor met the primary endpoint of overall survival. Results will be presented at an upcoming medication meeting. Sintilimab has been approved in China for 3 other indications.

Source:

Biospace Inc.